News

Efficacy and Safety of Gene Therapy Using Adeno-Associated Virus Vector in Patients with Choroideremia
Choroideremia (CHM) is a rare genetically conditioned retinal disease caused by mutations in the CHM gene, leading to a lack of production of the protein REP1 (ras-associated binding escort protein 1). Currently, there is no approved treatment for CHM. The aim of the study (Tübingen Choroideremia Gene Therapy) published last year in the journal JAMA Ophthalmology was to evaluate the safety and efficacy of subretinally applied gene therapy using an adeno-associated virus vector (AAV2), designed to deliver a functional copy of the CHM gene to…

Results of ATTUNE Total Knee Replacement Implantation – Data from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

Young man with nephrotic syndrome and portal vein thrombus successfully treated with edoxaban − case report

Options of Anticoagulant Therapy During Pregnancy: Focus on Fondaparinux

Alternative to benzodiazepines or clomethiazole in the treatment of alcohol withdrawal syndrome?

Importance of pH in Care for Stoma Patients

Combination of SGLT2 inhibitors with metformin in terms of mechanism of action

Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy

Basic Information on the Spread and Course of COVID-19 Infection in China: What We Know So Far?

Rapid Diagnosis of Depression in Primary Care Settings
Conferences
News from the world of medicine
All conferences
Popular this week
- How Do Chronic and Acute Stress Affect the Gastrointestinal Tract?
- AI Could Transform Cancer Treatment by Precisely Identifying Tumor Cells
- “Clinical Bites” – Research Highlights 2025/28
- Europe Reads DNA: Genomic Projects Shaping the Future
- Why Do We Forget About the Nocebo Effect, Even Though It Is Stronger Than the Placebo Effect?